NCT07103746 Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy Status RECRUITING Phase PHASE2
NCT06434363 Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders Status RECRUITING Phase PHASE1/PHASE2
NCT01489956 A Study to Determine the Immunogenicity and Oral Tolerance to Keyhole Limpet Hemocyanin (KLH) Status TERMINATED Phase EARLY_PHASE1